Publication | Closed Access
Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)
25
Citations
0
References
2016
Year
Diabetes ManagementMedicineInsulin ManagementDiabetesBasal Insulin AloneClinical TrialsType 2Sustain 5PharmacotherapyDiabetes MellitusPharmacology
No additional data available for this publication yet. Check back later!